Virica Biotech

📍 Ottawa, Canada🗓 Founded 2018👥 44 employees💰 Last funded Jul 2024
Biotechnology Research🌐 viricabiotech.com
Website LinkedIn
Cell and gene therapies, as well as viral vaccines, need higher production yields—and thats where we excel. We significantly increase yields by targeting the innate cellular defenses within production cells. These natural defenses, designed to combat foreign genetic material and inhibit viral replication, can hinder your process. Our solution is a unique panel small molecules which make up our Viral Sensitizer (VSETM) platform, which dampen cellular defenses. Using an innovative high-throughput screening process, we have developed a library of novel VSEs. Virica continues to leverage this advanced technology to pinpoint the most synergistic Viral Sensitizer molecules from our library, tailored to any virus or cell line. We customize formulations of these Viral Sensitizers to enhance virus yield in your manufacturing process or optimize the effectiveness of your viral therapies. The result is higher yields and improved quality, helping to reduce costs and improve patient access.
2
Total investors
0
Early stage
1
Mid stage
1
Late stage
2018
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
1
Canada
1
Frequently asked questions
Who invested in Virica Biotech?
Virica Biotech has 2 investors on record on gritt.io, 1 mid-stage and 1 late-stage investors.
When did Virica Biotech last raise funding?
The most recent investment in Virica Biotech recorded on gritt.io was in July 2024.
When was Virica Biotech founded?
Virica Biotech was founded in 2018.
What industry is Virica Biotech in?
Virica Biotech operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Virica Biotech based?
Virica Biotech is headquartered in Ottawa, Canada.